The meta-analysis mentioned above showed that patients with cancer who received bevacizumab also had a significant and dose-dependent increase in risk of hypertension (relative risk 3.0 with low-dose, 7.5 with high-dose bevacizumab).53 Hypertension must therefore be well controlled before starting therapy with atezolizumab plus bevacizumab; the most commonly used treatments are angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.54 The gene discussed is ACE; the disease is hypertensive disorder.